title: Peripheral blood stem cell transplantation for POEMS syndrome.
abstract: In common with other plasma cell dyscrasias in which a small tumour burden is associated with severe clinical symptoms (notably systemic AL amyloidosis) the possible benefits of dose intensification are yet to be fully explored in POEMS syndrome. One important issue is whether the toxicity of the procedure is significantly increased in this group. We report two cases of POEMS syndrome with solitary asymptomatic bone lesions treated with high-dose melphalan (200 mg/m(2)) and peripheral blood stem cell (PBSC) rescue. In both cases there was minimal peri-transplant morbidity and a subsequent substantial and maintained improvement in the peripheral neuropathy.
authors.affiliation: Department of Haematology, University College London Hospitals, UK.
authors.forename: K S
authors.initials: KS
authors.lastname: Peggs
authors.forename: S
authors.initials: S
authors.lastname: Paneesha
authors.forename: P D
authors.initials: PD
authors.lastname: Kottaridis
authors.forename: R K
authors.initials: RK
authors.lastname: Chakraverty
authors.forename: G
authors.initials: G
authors.lastname: Tobias
authors.forename: M
authors.initials: M
authors.lastname: Reilly
authors.forename: P
authors.initials: P
authors.lastname: Mahendra
authors.forename: K
authors.initials: K
authors.lastname: Yong
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000633:toxicity; D008875:Middle Aged; D016878:POEMS Syndrome / Q000175:diagnosis / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D008558:Melphalan